Zenarestat

Zenarestat
Names

IUPAC name 3-[(4-Bromo-2-fluorophenyl)methyl]-7-chloro-3,4-dihydro-2,4-dioxo-1(2H)-quinazolineacetic acid
Identifiers
CAS Registry Number	112733-06-9
ChemSpider	5522
InChI InChI=1S/C17H11BrClFN2O4/c18-10-2-1-9(13(20)5-10)7-22-16(25)12-4-3-11(19)6-14(12)21(17(22)26)8-15(23)24/h1-6H,7-8H2,(H,23,24) Key: SXONDGSPUVNZLO-UHFFFAOYSA-N InChI=1/C17H11BrClFN2O4/c18-10-2-1-9(13(20)5-10)7-22-16(25)12-4-3-11(19)6-14(12)21(17(22)26)8-15(23)24/h1-6H,7-8H2,(H,23,24) Key: SXONDGSPUVNZLO-UHFFFAOYAB
Jmol-3D images	Image
PubChem	5724
SMILES C1=CC2=C(C=C1Cl)N(C(=O)N(C2=O)CC3=C(C=C(C=C3)Br)F)CC(=O)O
Properties
Molecular formula	C₁₇H₁₁BrClFN₂O₄
Molar mass	441.64 g·mol⁻¹
Melting point	223 to 224 °C (433 to 435 °F; 496 to 497 K)
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
Infobox references

Zenarestat (FK-366; FR-74366) is an aldose reductase inhibitor. It was intended to be used in the treatment of diabetic neuropathy and cataract.

References

M. Hashimoto et al., EP 218999; eidem, US 4734419 (1987, 1988 both to Fujisawa)
Inhibition kinetics and effect on sorbitol accumulation: S. Ao et al., Metabolism 40, 77 (1991)
Pharmacokinetics and metabolism in diabetic rats: Y. Tanaka et al., Drug Metab. Dispos. 21, 677 (1993)
M. Kanamaru et al., J. Clin. Pharmacol. 33, 1122 (1993).